Stay updated on Isatuximab Combo in High-Risk Smoldering MM Clinical Trial
Sign up to get notified when there's something new on the Isatuximab Combo in High-Risk Smoldering MM Clinical Trial page.

Latest updates to the Isatuximab Combo in High-Risk Smoldering MM Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe history page shows a new revision entry 'Revision: v3.3.3' and removes the 'HHS Vulnerability Disclosure' link and the earlier 'Revision: v3.3.2' entry from the footer, which are administrative, non-content changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedA References section and an updated Study Status were added, with a new version entry (33) appearing on 2025-12-05.SummaryDifference0.3%

- Check42 days agoChange DetectedA new page revision (v3.3.2) replaces the previous revision (v3.3.1); no study data, statuses, or user-interaction elements appear to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedDifference0.1%

- Check56 days agoChange DetectedThe banner about government operating status was removed from the page. The rest of the study record, including version history and trial details, remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check70 days agoChange DetectedNew screenshot shows only minor visual/layout adjustments on the Record History page; no substantive changes to version entries or study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Isatuximab Combo in High-Risk Smoldering MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Isatuximab Combo in High-Risk Smoldering MM Clinical Trial page.